[go: up one dir, main page]

ME00513B - Azabicikloalkani kao modulatori ccr5 - Google Patents

Azabicikloalkani kao modulatori ccr5

Info

Publication number
ME00513B
ME00513B MEP-2008-837A MEP83708A ME00513B ME 00513 B ME00513 B ME 00513B ME P83708 A MEP83708 A ME P83708A ME 00513 B ME00513 B ME 00513B
Authority
ME
Montenegro
Prior art keywords
azabicycloalkanes
modulators
ccr5 modulators
compounds
ccr5
Prior art date
Application number
MEP-2008-837A
Other languages
English (en)
French (fr)
Inventor
Duncan Robert Armour
David Anthony Price
Blanda Luzia Christa Stammen
Anthony Wood
Manoussos Perros
Martin Paul Edwards
Original Assignee
Pfizer Ltd
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828420.1A external-priority patent/GB9828420D0/en
Priority claimed from GBGB9921375.3A external-priority patent/GB9921375D0/en
Application filed by Pfizer Ltd, Pfizer filed Critical Pfizer Ltd
Publication of ME00513B publication Critical patent/ME00513B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Jedinjenja formule (l) [Regionα] - [Regionβ] - [Regionγ] - [Regionδ], koja su korisna kao modulatori aktivnosti hemokina. Ovaj pronalazak takođe daje farmaceutske formulacije i postupke tretmana koji koriste ova jedinjenja.
MEP-2008-837A 1998-12-23 1999-12-23 Azabicikloalkani kao modulatori ccr5 ME00513B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9828420.1A GB9828420D0 (en) 1998-12-23 1998-12-23 CCR5 antagonists useful as anti-hiv agents
GBGB9921375.3A GB9921375D0 (en) 1999-09-10 1999-09-10 CCR5 Modulators
PCT/IB1999/002048 WO2000038680A1 (en) 1998-12-23 1999-12-23 Azabicycloalkanes as ccr5 modulators

Publications (1)

Publication Number Publication Date
ME00513B true ME00513B (me) 2011-10-10

Family

ID=26314899

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-837A ME00513B (me) 1998-12-23 1999-12-23 Azabicikloalkani kao modulatori ccr5

Country Status (48)

Country Link
US (1) US6586430B1 (me)
EP (1) EP1140085B1 (me)
JP (1) JP3602795B2 (me)
KR (1) KR100425612B1 (me)
CN (1) CN1331591A (me)
AP (1) AP1697A (me)
AR (1) AR024233A1 (me)
AT (1) ATE505190T1 (me)
AU (1) AU763644B2 (me)
BG (1) BG65448B1 (me)
BR (1) BRPI9917007B8 (me)
CA (1) CA2350073C (me)
CO (1) CO5300387A1 (me)
CR (2) CR9879A (me)
CU (1) CU23344A3 (me)
CY (1) CY1111504T1 (me)
CZ (1) CZ300926B6 (me)
DE (1) DE69943352D1 (me)
DK (1) DK1140085T3 (me)
DZ (2) DZ2979A1 (me)
EA (1) EA004988B1 (me)
EE (1) EE05170B1 (me)
EG (1) EG24400A (me)
GC (1) GC0000117A (me)
GE (1) GEP20033131B (me)
HK (1) HK1039902A1 (me)
HR (2) HRP20010468B1 (me)
HU (1) HU228754B1 (me)
ID (1) ID28965A (me)
IL (2) IL143512A0 (me)
IS (1) IS5944A (me)
MA (1) MA26714A1 (me)
ME (1) ME00513B (me)
NO (1) NO330677B1 (me)
NZ (1) NZ511794A (me)
OA (1) OA11735A (me)
PA (1) PA8487201A1 (me)
PE (1) PE20001420A1 (me)
PL (1) PL201875B1 (me)
PT (1) PT1140085E (me)
RS (1) RS51701B (me)
SI (1) SI1140085T1 (me)
SK (1) SK287020B6 (me)
TN (1) TNSN99252A1 (me)
TR (1) TR200101793T2 (me)
TW (1) TW577888B (me)
UA (1) UA72750C2 (me)
WO (1) WO2000038680A1 (me)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EP1118858A3 (en) * 2000-01-12 2003-07-09 Pfizer Limited Assay method
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SK286129B6 (sk) 2000-05-26 2008-04-07 Pfizer Inc. Tropánové deriváty, ich použitie, spôsob a medziprodukt na ich výrobu, kombinácia a farmaceutická kompozícia s ich obsahom
US6667314B2 (en) * 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6531484B2 (en) 2000-10-11 2003-03-11 Merck & Co., Inc. Pyrrolidine modulators of CCR5 chemokine receptor activity
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
EP1354587A1 (en) * 2000-12-22 2003-10-22 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
TW200305395A (en) * 2002-03-15 2003-11-01 Novartis Ag Organic compounds
CN1324025C (zh) * 2002-04-08 2007-07-04 美国辉瑞有限公司 作为ccr5调节剂的托烷衍生物
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
CA2485825A1 (en) * 2002-05-23 2003-12-04 Pfizer Inc. Method for identification of a ligand whereby receptor residence time is measured
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
JP4666256B2 (ja) * 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
RU2005118407A (ru) * 2002-12-13 2006-03-10 СмитКлайн Бичем Корпорейшн (US) Производные пиперидина в качестве антагонистов ccr5
JP2006514950A (ja) 2002-12-13 2006-05-18 スミスクライン ビーチャム コーポレーション Ｃｃｒ５拮抗薬としてのシクロプロピル化合物
NZ542304A (en) 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
JP4710606B2 (ja) 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
ES2285485T3 (es) * 2003-07-31 2007-11-16 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5.
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
WO2005023810A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
DE602004010708T2 (de) * 2003-10-03 2008-12-04 Pfizer Inc. Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
BRPI0506548A (pt) * 2004-01-30 2007-05-02 Euro Celtique Sa métodos para produzir compostos de 4-tetrazolil-4-fenilpiperidina
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
MXPA06011884A (es) * 2004-04-14 2006-12-14 Pfizer Compuestos de imidazol unidos a azufre para el tratamiento del virus de inmunodeficiencia humana.
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
ES2297727T3 (es) 2004-06-09 2008-05-01 F. Hoffmann-La Roche Ag Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos.
PE20090123A1 (es) 2004-09-13 2009-03-10 Ono Pharmaceutical Co Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
JP2008534654A (ja) * 2005-04-08 2008-08-28 ノイロサーチ アクティーゼルスカブ （＋）−及び（−）−８−アルキル−３−（トリフルオロアルキルスルホニルオキシ）−８−アザビシクロ（３．２．１）オクト−２−エン
AU2006233537A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
ES2277745B1 (es) * 2005-06-14 2008-06-01 Laboratorios Almirall S.A. Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
US20080015833A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition of protein misfolding
US20080015835A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for treating disease
US20090082344A1 (en) * 2006-07-13 2009-03-26 Searete Llc Methods and systems for treating disease
US20080014572A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
EP2121676A1 (en) * 2006-12-19 2009-11-25 Auspex Pharmaceuticals, Inc. Preperation and utility of ccr5 inhibitors
MX2010002449A (es) 2007-08-31 2010-09-07 Purdue Pharma Lp Compuestos de piperidina tipo quinoxalina sustituida y uso de los mismsos.
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2011011652A1 (en) 2009-07-24 2011-01-27 Glaxosmithkline Llc Therapeutic compounds
EP2552429A1 (en) 2010-04-02 2013-02-06 Phivco-1 LLC Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
JP2014518610A (ja) 2011-03-09 2014-08-07 リチャード ジー． ペステル 前立腺癌細胞系、遺伝子シグネチャー及びその使用
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JP6518585B2 (ja) * 2012-05-14 2019-05-22 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
EP3826659B1 (en) * 2018-07-10 2024-06-19 Rush University Medical Center Immunomodulator for use in the treatment of a bacterial infection
CN115443133B (zh) 2020-02-19 2024-02-20 伊契洛夫科技有限公司 改进的抗抑郁疗法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2021257420A1 (en) * 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
PH30413A (en) 1992-03-26 1997-05-09 Boehringer Ingelheim Italia Crystalline forms of endo-2,3-dihydro-n-(8-methyl)-8-azabicyclo-(3,2,1)oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
DE19500120A1 (de) * 1995-01-04 1996-07-11 Bayer Ag Neue acylierte Pseudopeptide mit trifluormethyl-subsstituiertem 2-Azabicyclooctan
GB9502644D0 (en) * 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
KR100313641B1 (ko) * 1996-03-29 2002-02-19 디. 제이. 우드, 스피겔 알렌 제이 6-페닐피리딜-2-아민유도체
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998002151A2 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
CA2261633A1 (en) * 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
EP1003743A4 (en) 1997-01-21 2001-04-11 Merck & Co Inc 3,3-DISBSTITUED PIPERIDINE LIKE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
WO1999009984A1 (en) 1997-08-28 1999-03-04 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
JP2002501052A (ja) * 1998-01-21 2002-01-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ケモカイン受容体アンタゴニストおよびその使用方法

Also Published As

Publication number Publication date
UA72750C2 (en) 2005-04-15
BG65448B1 (bg) 2008-08-29
TNSN99252A1 (fr) 2005-11-10
CA2350073A1 (en) 2000-07-06
ATE505190T1 (de) 2011-04-15
GC0000117A (en) 2005-06-29
CZ20012298A3 (cs) 2002-09-11
CO5300387A1 (es) 2003-07-31
HRP20120132A8 (hr) 2017-11-03
IL143512A (en) 2013-06-27
AP1697A (en) 2006-12-22
SI1140085T1 (sl) 2011-08-31
CA2350073C (en) 2007-04-17
TW577888B (en) 2004-03-01
ID28965A (id) 2001-07-19
AU763644B2 (en) 2003-07-31
HRP20120132B1 (hr) 2018-01-26
NO330677B1 (no) 2011-06-06
US6586430B1 (en) 2003-07-01
HRP20010468B1 (en) 2012-06-30
HUP0104795A3 (en) 2002-05-28
EE05170B1 (et) 2009-06-15
SK287020B6 (sk) 2009-09-07
YU38801A (sh) 2005-06-10
WO2000038680A1 (en) 2000-07-06
OA11735A (en) 2005-05-12
CY1111504T1 (el) 2015-08-05
DK1140085T3 (da) 2011-06-27
IL143512A0 (en) 2002-04-21
JP3602795B2 (ja) 2004-12-15
HUP0104795A2 (hu) 2002-04-29
DZ3326A1 (fr) 2005-05-29
CN1331591A (zh) 2002-01-16
JP2002533393A (ja) 2002-10-08
NZ511794A (en) 2003-10-31
NO20013183L (no) 2001-08-08
AP2001002186A0 (en) 2001-06-30
BR9917007A (pt) 2001-10-30
HRP20010468A2 (en) 2003-02-28
DZ2979A1 (fr) 2005-01-30
BG105721A (en) 2002-02-28
HU228754B1 (en) 2013-05-28
PT1140085E (pt) 2011-06-16
CZ300926B6 (cs) 2009-09-09
CR6392A (es) 2006-08-09
EA200100589A1 (ru) 2002-02-28
PE20001420A1 (es) 2000-12-18
KR100425612B1 (ko) 2004-04-01
NO20013183D0 (no) 2001-06-25
BRPI9917007B1 (pt) 2016-07-26
AR024233A1 (es) 2002-09-25
EE200100345A (et) 2002-12-16
PL349495A1 (en) 2002-07-29
EA004988B1 (ru) 2004-10-28
CR9879A (es) 2008-06-20
PL201875B1 (pl) 2009-05-29
PA8487201A1 (es) 2002-02-21
DE69943352D1 (de) 2011-05-26
HK1039902A1 (zh) 2002-05-17
BRPI9917007B8 (pt) 2021-05-25
CU23344A3 (es) 2009-02-20
AU1675100A (en) 2000-07-31
GEP20033131B (en) 2003-12-25
SK8752001A3 (en) 2003-02-04
MA26714A1 (fr) 2004-12-20
TR200101793T2 (tr) 2001-12-21
IS5944A (is) 2001-05-15
KR20010089701A (ko) 2001-10-08
EP1140085B1 (en) 2011-04-13
EG24400A (en) 2009-04-29
RS51701B (sr) 2011-10-31
EP1140085A1 (en) 2001-10-10
HRP20120132A2 (hr) 2012-03-31

Similar Documents

Publication Publication Date Title
ME00513B (me) Azabicikloalkani kao modulatori ccr5
YU40701A (sh) Piperidini kao modulatori ccr5
CA2292984A1 (en) Ccr5 modulators
ATE355288T1 (de) Verbindungen und therapeutische methoden
ATE233754T1 (de) Diphenyl-piperidin derivate
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
SE9804212D0 (sv) Compounds
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
ATE368664T1 (de) Pteridinon-derivate als modulatoren der chemokinrezeptor-aktivität
ATE315563T1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
ATE253359T1 (de) Antithrombotische mittel
SE9902551D0 (sv) Novel compounds
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
MXPA02002007A (es) Compuestos de bencimidazol sustituidos con alcoxi, preparaciones farmaceuticas que contienen los mismos, metodos para usarlos.
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
TR199901385T2 (xx) Piperidin t�revleri.
SE9803107D0 (sv) Novel Compunds
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
ECSP993298A (es) Moduladores de ccr5
ECSP993296A (es) Moduladores de ccr5
DE60143020D1 (de) 9-alkylamino-1-nitroacridin-derivate
UA34406A (uk) Засіб для лікування розсіяного склерозу, спосіб лікування з його використанням та фармацевтична упаковка